SCODiA Report by MLBI Lab

Single-Cell Landscape of Breast Cancer Reveals Subtype-Specific Mechanisms, Tumor Microenvironment Dynamics, and Therapeutic Vulnerabilities

This report comprehensively characterizes the single-cell landscape of human breast tissue, comparing normal samples with ER+, HER2+, and Triple-Negative Breast Cancer (TNBC) subtypes. We observe significant genomic instability and aneuploidy in tumor-origin epithelial cells, alongside profound remodeling of the tumor microenvironment (TME). Subtype-specific shifts in immune cell populations, particularly T cells and macrophages, and distinct cell-cell interaction networks reveal mechanisms of tumor progression and immune evasion, offering insights into potential therapeutic vulnerabilities.

Contents

  1. Dataset overview
  2. UMAP Visualization of Breast Tissue Single-Cell RNA-Seq Data by Condition, Sample, Cell Type, and Ploidy
  3. UMAP Visualization of Major Cell Type Scores, Ploidy Status, and Major Cell Type Annotations
  4. Celltype_subset Marker Expression Dot Plot Analysis
  5. Copy Number Variation Analysis in Tumor-Origin and Unassigned Cells Grouped by Sample
  6. CNV-based UMAP Visualization of Breast Tissue Single-Cell Data
  7. Minor Cell Type Population Analysis across Breast Cancer Subtypes
  8. T Cell and Innate Lymphoid Cell Subpopulation Analysis Across Breast Cancer Subtypes and Normal Tissue
  9. T Cell Subset Population Analysis Across Breast Cancer Conditions
  10. Macrophage Subset Population Analysis Across Breast Cancer Subtypes
  11. Macrophage Subset Population Dynamics in Breast Cancer Subtypes
  12. Ploidy Status of Tumor-Origin (Epithelial) and Unassigned Cells Across Breast Cancer Subtypes
  13. 유방암 아형 및 정상 조직의 세포 간 상호작용 패턴 분석
  14. Normal Breast Tissue Cell-Cell Interaction Landscape
  15. Immune Checkpoint and Cell Cycle Gene-Related Cell-Cell Interactions in Breast Cancer Subtypes
  16. Condition-Specific Cell-Cell Interaction Patterns in Breast Cancer Subtypes
  17. Epithelial Cell Condition-Specific Surfaceome Markers in Breast Cancer Subtypes
  18. Macrophage Condition-Specific Surfaceome Markers in Breast Cancer
  19. Fibroblast Condition-Specific Surfaceome Markers in Breast Cancer
  20. T cell CD4+ Condition-Specific Surfaceome Marker Analysis in Breast Cancer Subtypes
  21. Differential Expression of Cell Cycle Genes in Epithelial Cells Across Breast Cancer Subtypes
  22. Epithelial Cell Gene Ontology Analysis Across Breast Tissue Conditions
  23. Gene Set Enrichment Analysis (GSEA) of Breast Cancer Cell Types by Subtype
  24. Discussion
  25. Query List

0. Dataset overview

Dataset Summary:

1. UMAP Visualization of Breast Tissue Single-Cell RNA-Seq Data by Condition, Sample, Cell Type, and Ploidy

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a series of Uniform Manifold Approximation and Projection (UMAP) plots generated from single-cell RNA-seq data of human breast tissue, comprising 85,449 cells and 26,440 genes. The UMAPs visualize the cellular landscape based on transcriptional similarity, colored by various metadata attributes including Condition, sample, celltype_major, celltype_minor, ploidy_dec, and celltype_subset. This comprehensive visualization allows for an initial assessment of data quality, cell type annotation robustness, and the distribution of cells across different conditions and samples.

Visual Summary

The UMAP plots reveal a well-structured embedding where cells group by biological similarity.

Biological Interpretation

  1. Tumor Microenvironment Heterogeneity: The UMAPs underscore the significant cellular heterogeneity within the breast tissue microenvironment. The clear separation of Normal cells from malignant cells confirms disease-specific transcriptional changes. The distinct yet overlapping clustering of ER+, HER2+, and Triple negative tumors highlights their unique biological underpinnings while also suggesting shared features or cellular components across different breast cancer subtypes.
  1. Robust Cell Type Annotation: The consistent and well-separated clustering of cells according to celltype_major, celltype_minor, and celltype_subset demonstrates the high quality and resolution of the cell type annotations. The identification of detailed subsets like specific T cell populations (e.g., Th1, Treg, Cytotoxic T cells), macrophage polarization states (M1, M2 subtypes), and distinct epithelial cell subtypes (Luminal, Mammary) provides a solid foundation for downstream analyses.
  2. Malignancy and Aneuploidy: The strong co-localization of Aneuploid cells with Epithelial cell clusters from tumor samples provides compelling evidence for the malignant nature of these epithelial cells. Aneuploidy, a hallmark of cancer characterized by an abnormal number of chromosomes, is a common feature of tumor cells, especially epithelial-derived cancers like breast cancer. Its clear segregation from diploid cells strongly suggests successful identification of the neoplastic compartment. (GeneCards: Aneuploidy in Cancer)
  3. Immune and Stromal Cell Compartmentalization: Immune cells (T cells, Myeloid cells, B cells) and stromal cells (Fibroblasts, Endothelial cells) form distinct communities, reflecting their specialized functions and unique gene expression programs within the tumor microenvironment. Their distribution, often peripheral to the main epithelial clusters, suggests their role in interacting with and influencing the tumor core.

Annotation Notes

2. UMAP Visualization of Major Cell Type Scores, Ploidy Status, and Major Cell Type Annotations

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents UMAP visualizations of single-cell RNA-seq data from human breast tissue, integrating major cell type scores, inferred ploidy status, and final major cell type annotations. The primary goal is to assess the quality of cell type identification, understand the overall cellular architecture, and identify potentially malignant cell populations within the dataset.

Visual Summary

The UMAP plots provide a comprehensive overview of cell identities and characteristics across the 85,449 cells and 26,440 genes.

Biological Interpretation

  1. Robust Cell Type Annotation: The strong congruence between the HiCAT_major_score plots and the celltype_major annotation UMAP demonstrates that the computational methods effectively identified and delineated distinct major cell populations. The high scores for specific cell types consistently co-localize with their corresponding annotated clusters, validating the quality of the cell identity assignment.
  2. Identification of Malignant Epithelial Cells: A crucial observation is the substantial overlap between the Epithelial cell cluster and cells designated as Aneuploid in the ploidy_dec plot. Given that the 'Tumor origin celltype' is specified as 'Epithelial cell' and aneuploidy is a hallmark of cancer cells, this strongly suggests that these aneuploid epithelial cells represent the malignant tumor cell population within the breast cancer samples. Conversely, diploid epithelial cells likely represent normal mammary epithelial cells. This distinction is fundamental for downstream analyses aimed at understanding tumor-specific biology. GeneCards: AN EUPLOIDY
  3. Heterogeneity of the Tumor Microenvironment (TME): The presence and clear clustering of various non-malignant cell types, including diverse immune cells (T cells, B cells, Myeloid cells, Mast cells), stromal cells, and endothelial cells, reflect the complex cellular composition of the breast tissue and, particularly, the tumor microenvironment in cancer conditions (TNBC, HER2+, ER+). These distinct populations are critical components of tumor progression, immune surveillance, and therapeutic response. PubMed: Tumor Microenvironment Breast Cancer
  4. Overall Dataset Structure: The UMAP embedding effectively visualizes the inherent biological structure of the single-cell dataset, clustering cells with similar transcriptional profiles together. This organized representation is essential for exploring cell-type-specific gene expression, pathway activities, and cell-cell interactions across different conditions.

Clinical or Translational Implications

The ability to clearly distinguish malignant (aneuploid epithelial) cells from normal cells and various components of the tumor microenvironment at single-cell resolution is paramount for breast cancer research. This foundational annotation allows for:

3. Celltype_subset Marker Expression Dot Plot Analysis

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the expression of marker genes across different celltype_subset annotations within the provided single-cell RNA-seq dataset from breast tissue. The dot plot displays both the fraction of cells expressing a given gene (dot size) and the mean expression level of that gene (dot color intensity) within each cell type group. The primary goal is to assess the robustness and specificity of the celltype_subset annotations by examining whether each cell type preferentially expresses its expected marker genes. Markers were selected to be relatively specific, prioritizing surfaceome genes and excluding those common to three or more cell groups.

Visual Summary

The dot plot demonstrates a strong diagonal pattern, where each celltype_subset predominantly expresses the marker genes specifically grouped and highlighted for it along the x-axis. This visually confirms that the annotated cell types are largely distinct based on their gene expression profiles.

Biological Interpretation

The marker expression patterns largely support the assigned celltype_subset identities within the breast tissue context. Many well-established lineage-specific and subtype-specific markers are highly and specifically expressed in their corresponding cell clusters. This indicates a robust initial annotation of the cellular landscape. For example, the clear distinction of lymphatic endothelial cells via PROX1/PDPN, luminal epithelial cells via KRT8/18/19/ESR1, plasma cells via PRDM1/SDC1, and smooth muscle cells via ACTA2/MYL9 demonstrates the quality of the cell type resolution. The presence of ACTA2 in fibroblasts could reflect the activation of fibroblasts into myofibroblasts, which are particularly relevant in breast cancer progression and fibrosis.

Annotation Notes

Overall, the celltype_subset annotations are well-supported by the specific marker gene expression patterns observed in this dot plot. The consistent diagonal expression of dedicated marker genes within their respective cell types indicates a high degree of confidence in the current cellular identity assignments.

However, a few areas warrant further consideration for potential refinement or deeper characterization:

4. Copy Number Variation Analysis in Tumor-Origin and Unassigned Cells Grouped by Sample

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates copy number variations (CNVs) within tumor-origin epithelial cells and cells currently designated as 'unassigned' across various breast cancer samples and normal controls. Cells were grouped by individual sample to highlight sample-specific genomic alterations. The goal is to visualize the genomic landscape of these cell populations and to identify significantly amplified regions, providing insights into tumor biology, genomic instability, and potentially aiding in the re-evaluation of 'unassigned' cell identities.

Visual Summary

The analysis presents two visualizations:

  1. CNV Heatmap (log2(CNR)): This heatmap displays the estimated log2(Copy Number Ratio, CNR) for tumor-origin (Epithelial cell) and 'unassigned' cells, aggregated by sample, across the entire genome (represented by genomic spots on the x-axis, grouped by chromosome). The y-axis represents individual samples, prefixed with their inferred ploidy status (Diploid or Aneuploid) and condition (e.g., ER+, HER2+, TNBC, Normal). Red hues indicate genomic amplifications (log2(CNR) > 0), while blue hues indicate genomic deletions (log2(CNR) < 0).
  1. Summary of Significantly Amplified Copy Number Regions: This heatmap summarizes the frequency of significant amplification for various cytogenetic bands across the analyzed samples. The intensity of blue coloration indicates higher frequency of amplification within a given sample for a specific genomic region.

Biological Interpretation

The analysis strongly highlights the genomic instability characteristic of breast cancer, particularly within the Epithelial cell population, which is designated as the tumor-origin cell type. The clear demarcation between 'Diploid' and 'Aneuploid' samples based on CNV burden validates the ploidy_dec annotation as a reliable indicator of malignancy.

The identification of widespread CNVs in Aneuploid samples from various breast cancer conditions (ER+, HER2+, TNBC) is consistent with established knowledge of cancer genomics. The specific amplification of ERBB2 at 17q12 in HER2+ samples serves as a powerful validation of the sample classification and the underlying molecular drivers of this subtype. The recurrent amplification of SOX2 at 3q26.33 across multiple tumor subtypes suggests its potential role in promoting proliferation, stemness, or therapeutic resistance in a broader context of breast cancer.

Crucially, the CNV patterns observed in unassigned cells are highly similar to those found in Epithelial cells within the same tumor samples. This suggests that a significant portion of the 'unassigned' cell population in cancer samples likely represents malignant epithelial cells that may have altered transcriptional profiles (e.g., due to dedifferentiation, epithelial-mesenchymal transition, or stress responses) causing them to deviate from standard epithelial cell markers and thus be difficult to annotate by transcriptomics alone. Their shared CNV landscape, a robust indicator of malignancy, supports their re-classification as tumor cells.

Clinical or Translational Implications

The observed CNV patterns provide valuable insights with several clinical implications:

5. CNV-based UMAP Visualization of Breast Tissue Single-Cell Data

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a Uniform Manifold Approximation and Projection (UMAP) plot, generated using copy number variation (CNV) estimates (obsm['X_cnv']), to visualize the landscape of 85,449 single cells from human breast tissue. The UMAP plots are colored by celltype_major, celltype_minor, ploidy_dec (ploidy inference label), condition (Normal, TNBC, HER2+, ER+), and sample to reveal the underlying structure and relationships between cell states, genetic alterations, and disease context. The embedding configuration specifically leveraged CNV data, which is crucial for identifying tumor cells that often harbor significant genomic instability.

Visual Summary

Cell Type Distribution

Ploidy Status and Disease Conditions

Sample-Level Variation

Biological Interpretation

The UMAP projection, driven by CNV estimates, provides robust evidence for genomic alterations distinguishing tumor cells from normal cells and potentially between different tumor subtypes.

Clinical or Translational Implications

6. Minor Cell Type Population Analysis across Breast Cancer Subtypes

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis provides a detailed view of the cellular composition, specifically focusing on the minor cell types, across different breast cancer subtypes (ER+, HER2+, TNBC) and Normal breast tissue samples. The stacked bar plot visualizes the proportional abundance of 15 distinct celltype_minor populations within each individual sample, allowing for a comparative assessment of the cellular microenvironment across conditions. This type of analysis is crucial for understanding the overall tissue architecture and the shifts in cell populations that occur in disease states, particularly in the tumor microenvironment (TME).

Visual Summary

The visualization consists of stacked bar plots, grouped by condition (ER+, HER2+, Normal, TNBC), with each bar representing a single sample. The y-axis indicates the percentage of cells, summing to 100% for each sample.

Immune Cell Infiltration Patterns

Biological Interpretation

The observed cell type population distributions provide critical biological insights into the distinct microenvironments of different breast cancer subtypes:

Immune Infiltration as a Subtype Hallmark

Clinical or Translational Implications

7. T Cell and Innate Lymphoid Cell Subpopulation Analysis Across Breast Cancer Subtypes and Normal Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents the relative proportions of T cell and Innate Lymphoid Cell (ILC) subsets, along with NK cells, within the total T cell compartment (including ILCs/NK cells) across individual samples from Normal breast tissue, Estrogen Receptor-positive (ER+), Human Epidermal growth factor Receptor 2-positive (HER2+), and Triple-Negative Breast Cancer (TNBC) conditions. This stacked bar plot visualizes the immune microenvironment composition at a higher resolution (celltype_subset) within these lymphoid populations.

Visual Summary

The stacked bar plot shows the distribution of various T cell, ILC, and NK cell subsets for each sample, grouped by condition (ER+, HER2+, Normal, TNBC). Each bar represents 100% of these lymphoid cells within a given sample.

Biological Interpretation

The observed shifts in T cell and ILC subset populations reveal profound changes in the immune microenvironment of breast cancer compared to normal tissue.

  1. Immune Remodeling in Cancer: The most striking finding is the significant shift from an ILC/NK cell-dominant immune landscape in normal breast tissue to one predominantly characterized by adaptive T cells in all breast cancer subtypes. This indicates a robust immune response and extensive remodeling of the tumor microenvironment (TME) driven by the presence of cancerous cells.
  2. Dual Role of T Cells in Tumor Immunity:
  1. Depletion or Alteration of Innate Lymphoid Cells (ILCs) and NK Cells: The reduced relative proportions of ILCs and NK cells in breast cancer compared to normal tissue are notable. ILCs, including ILCreg and LTI, are important for tissue homeostasis and early immune responses. Their relative decrease could imply that the tumor microenvironment either displaces these cells, inhibits their expansion, or alters their phenotype and function, contributing to an immunosuppressive environment PubMed Search: ILCs tumor microenvironment. NK cells are critical for innate anti-tumor surveillance, and their reduction or dysfunction can impair tumor control.
  2. Subtype-Specific Nuances: While the general pattern of T cell dominance is observed across all cancer subtypes, the very strong presence of cytotoxic T cells and Tregs in TNBC aligns with its known higher immunogenicity and a more inflamed TME compared to other breast cancer subtypes.

Clinical or Translational Implications

These findings have several important implications for breast cancer diagnosis, prognosis, and therapeutic strategies:

8. T Cell Subset Population Analysis Across Breast Cancer Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional distribution of various T cell subsets (defined at the celltype_subset taxonomic level) across different breast cancer conditions: ER+ (Estrogen Receptor positive), HER2+ (Human Epidermal growth factor Receptor 2 positive), TNBC (Triple-Negative Breast Cancer), and Normal breast tissue. Boxplots visualize the cell type proportion for each subset, and significant differences between conditions are indicated with p-values (cutoff at p ≤ 0.1). This helps to understand how the immune landscape, specifically T cell-mediated immunity, varies in different breast cancer subtypes and in normal tissue.

Visual Summary

The boxplots display the proportion of nine distinct T cell subsets across four conditions. Key observations, based on significant p-values (p ≤ 0.1) and visual trends, include:

Th1 and Th2 cells:

ILCreg and ILC3(-):

Biological Interpretation

The distinct distribution of T cell subsets across breast cancer conditions highlights subtype-specific immune microenvironments:

Clinical or Translational Implications

The differential T cell subset profiles have several potential clinical implications:

9. Macrophage Subset Population Analysis Across Breast Cancer Subtypes

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the relative proportions of different macrophage subsets (M1, M2A, M2B, M2C, M2D) within the total macrophage population across individual samples from Normal breast tissue, Estrogen Receptor-positive (ER+), Human Epidermal growth factor Receptor 2-positive (HER2+), and Triple-Negative Breast Cancer (TNBC) conditions. This stacked barplot provides insights into the polarization state of macrophages in the tumor microenvironment (TME) of various breast cancer subtypes and normal tissue. Macrophage polarization into M1 (pro-inflammatory, anti-tumor) and various M2 subtypes (generally immunosuppressive, pro-tumorigenic) is a critical determinant of disease progression and response to therapy.

Visual Summary

The visualization presents stacked bar plots, with each bar representing a single sample and the stacked segments indicating the proportional representation of five distinct macrophage subsets: Macrophage (M1), Macrophage (M2A), Macrophage (M2B), Macrophage (M2C), and Macrophage (M2D).

Biological Interpretation

Macrophages are highly plastic cells that can polarize into different functional states, primarily M1 (classical activation) and M2 (alternative activation) subtypes.

The observed distribution suggests distinct macrophage immune microenvironments across breast cancer subtypes:

Clinical or Translational Implications

Understanding the specific polarization of macrophages in different breast cancer subtypes holds significant clinical implications:

10. Macrophage Subset Population Dynamics in Breast Cancer Subtypes

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional representation of specific macrophage subsets, Mac (M1) and Mac (M2B), within the breast tissue samples. The proportions are compared across different breast cancer conditions (ER+, TNBC, HER2+) relative to Normal tissue, providing insights into how these immune cell populations shift in the tumor microenvironment.

Visual Summary

The boxplots illustrate the celltype proportion for Mac (M1) and Mac (M2B) across Normal, ER+, TNBC, and HER2+ conditions:

Mac (M1) Proportion:

Mac (M2B) Proportion:

Biological Interpretation

The observed differential regulation of macrophage subsets highlights a complex remodeling of the immune landscape in breast cancer.

Clinical or Translational Implications

11. Ploidy Status of Tumor-Origin (Epithelial) and Unassigned Cells Across Breast Cancer Subtypes

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the proportion of cells categorized by their ploidy status (Aneuploid, Diploid, or Unclear) within the "Epithelial cell" and "unassigned" major cell types. The data is stratified by individual samples and further grouped by breast cancer conditions (ER+, HER2+, TNBC) and Normal tissue. Given that "Epithelial cell" is defined as the tumor-origin cell type, this analysis provides critical insights into the genomic stability of malignant and potentially malignant cell populations across different breast cancer subtypes.

Visual Summary

The bar plot effectively illustrates the ploidy distribution for epithelial and unassigned cells across various samples and conditions.

Biological Interpretation

The observed ploidy patterns strongly correlate with the malignant status and subtype of breast cancer, highlighting the role of aneuploidy as a hallmark of cancer.

Subtype-Specific Genomic Instability

Clinical or Translational Implications

12. 유방암 아형 및 정상 조직의 세포 간 상호작용 패턴 분석

Report figure

[Analysis Visualization Results]...

Analysis Overview

이 분석은 단일 세포 RNA 시퀀싱(scRNA-seq) 데이터를 기반으로 유방암 아형(ER+, HER2+, TNBC) 및 정상(Normal) 유방 조직에서 상위 80개 세포-세포 상호작용(Cell-Cell Interaction, CCI)을 시각화합니다. 주요 관심 세포 유형은 상피세포(Epithelial cell), 섬유아세포(Fibroblast), 대식세포(Macrophage), T세포(T cell)로 설정되었으며, 상피세포는 이배체(Diploid Epi)와 이수체(Aneuploid Epi)로 세분화되어 분석되었습니다. 상호작용의 강도(log2(mean))는 색상으로, 유의성(-log10(p))은 점의 크기로 표현됩니다.

Visual Summary

정상(Normal) 조직의 CCI

정상 조직에서는 주로 섬유아세포(Fibroblast)와 이배체 상피세포(Diploid Epithelial cell) 간의 광범위한 상호작용이 관찰됩니다.

ER+ 유방암의 CCI

ER+ 유방암에서는 대식세포(Macrophage)와 상피세포(Diploid Epi, Aneuploid Epi) 간의 상호작용이 지배적입니다.

HER2+ 유방암의 CCI

HER2+ 유방암은 T세포, 대식세포, 상피세포 간의 매우 복잡하고 다양한 상호작용을 보입니다.

TNBC (삼중 음성 유방암)의 CCI

TNBC는 ER+와 유사하게 대식세포-상피세포 간의 상호작용이 주를 이루지만, 몇 가지 독특한 패턴을 보입니다.

Biological Interpretation

정상 유방 조직은 조직 구조와 항상성 유지에 필수적인 섬유아세포와 상피세포 간의 탄탄한 세포외 기질 및 성장 인자 기반 상호작용을 보여줍니다. 반면, 모든 암 아형(ER+, HER2+, TNBC)에서는 종양 미세환경(TME)이 크게 변화하여 면역 세포(주로 대식세포, HER2+에서는 T세포)와 상피세포 간의 복잡한 상호작용이 두드러집니다.

아형별 특징:

Clinical or Translational Implications

이러한 세포-세포 상호작용 분석 결과는 유방암 치료를 위한 새로운 표적 및 전략을 식별하는 데 중요한 통찰력을 제공합니다.

치료 표적 발굴:

13. Normal Breast Tissue Cell-Cell Interaction Landscape

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the most significant and strongest cell-cell interactions (CCIs) within normal human breast tissue, as derived from single-cell RNA sequencing data. The plot_cci_dots tool was used to identify and represent up to 80 key ligand-receptor interactions between different cell types, specifically focusing on the 'Normal' condition. The results serve as a baseline for understanding healthy tissue homeostasis, which is crucial for interpreting disease-associated changes in other conditions (e.g., TNBC, HER2+, ER+).

Visual Summary

The dot plot effectively illustrates the complex network of cell-cell communication in normal breast tissue.

Overall, the plot reveals a rich array of interactions. Notably, Diploid Epi cells, Fib (Fibroblasts), and Endo (Endothelial cells) are central players, engaging in numerous significant interactions both among themselves and with each other. Several ligand-receptor systems, including various Integrin complexes, EGF family members, PDGF family, VEGF family, and Notch signaling, appear to be highly active. Some particularly strong interactions (bright yellow dots) are observed, such as FN1_integrin_a2b1_complex between Diploid Epi|Fib and Fib|Fib, and COL3A1_integrin_ADGRG1 in Endo|Fib interactions.

Biological Interpretation

The observed cell-cell interactions in normal breast tissue highlight crucial pathways for tissue maintenance, structural integrity, and physiological function.

Growth Factor Signaling:

Developmental and Homeostatic Pathways:

The observed interactions represent a healthy balance of cell growth, differentiation, adhesion, and stromal support necessary for the physiological function of the breast. The prominent role of Diploid Epi cells interacting with Fib and Endo cells underscores the importance of epithelial-stromal and epithelial-endothelial crosstalk for maintaining tissue homeostasis.

Clinical or Translational Implications

Understanding the baseline CCI network in normal breast tissue is critical for identifying dysregulated pathways in various breast cancer subtypes (TNBC, HER2+, ER+).

14. Immune Checkpoint and Cell Cycle Gene-Related Cell-Cell Interactions in Breast Cancer Subtypes

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interactions (CCI) mediated by a curated set of genes involved in immune checkpoint and cell cycle pathways across different breast tissue conditions: Normal, HER2-positive (HER2+), and Triple-Negative Breast Cancer (TNBC). The interactions are derived from single-cell RNA-seq data and visualized using dot plots, where dot size reflects the significance of the interaction (-log10(p-value)) and dot color represents the mean expression level (log2(mean)) of the ligand-receptor pair. The primary goal is to identify distinct communication patterns that could inform therapeutic targeting and understanding of disease mechanisms.

Visual Summary

The generated dot plots reveal striking differences in the landscape of immune checkpoint and cell cycle-related cell-cell interactions among the conditions:

Biological Interpretation

The observed CCI patterns offer critical insights into the breast cancer microenvironment:

  1. TGF-beta Signaling as a Conserved Interaction in Tumor Microenvironment: The consistent TGFB1_TGFbeta_receptor1 interaction between Macrophage|Macrophage cells in both HER2+ and TNBC conditions, while limited to this specific interaction in these aggressive subtypes, suggests a highly robust and potentially critical autocrine/paracrine loop within the macrophage population in tumor microenvironments. TGF-beta is a potent immunosuppressive cytokine, and its signaling is well-known to promote pro-tumorigenic functions in macrophages, such as M2 polarization, which fosters immune evasion, angiogenesis, and metastasis. The fact that this specific macrophage-macrophage communication remains prominent even when other interactions are lost or suppressed underscores its potential importance in these cancers. PubMed Search: TGFB1 macrophage M2 polarization cancer
  2. Loss of Diverse Cell-Cell Communication in Cancer Contexts: The dramatic reduction in observed cell-cell interactions in HER2+ and TNBC compared to Normal tissue, particularly involving epithelial, endothelial, and fibroblast cells, is a significant finding. This could indicate:
  1. Specific Interactions in Normal Tissue:

Clinical or Translational Implications

The findings from this cell-cell interaction analysis carry significant implications for understanding breast cancer biology and for therapeutic development:

  1. TGF-beta Pathway as a Therapeutic Target in HER2+ and TNBC: The consistent and prominent TGFB1_TGFbeta_receptor1 interaction between macrophages in HER2+ and TNBC strongly suggests that the TGF-beta signaling axis could be a critical therapeutic target in these aggressive breast cancer subtypes. Inhibiting TGF-beta signaling may re-educate pro-tumorigenic macrophages, enhance anti-tumor immunity, and potentially sensitize tumors to other therapies. Clinical trials investigating TGF-beta inhibitors in various cancers are ongoing. PubMed Search: TGF-beta inhibitors breast cancer clinical trials
  2. Understanding Tumor Microenvironment Remodeling: The shift from a diverse interactive network in normal tissue to a highly restricted macrophage-centric interaction in cancer highlights the profound remodeling of the tumor microenvironment. Further investigation into why other immune checkpoint and cell cycle-related interactions are lost or suppressed in tumor conditions could reveal novel mechanisms of immune evasion or tumor progression.
  3. Context-Dependent Roles of Signaling Pathways: The presence of robust EGFR and IFN-gamma receptor signaling in normal tissue for these specific ligand-receptor pairs, and their absence in the tumor conditions, underscores the context-dependent nature of these pathways. While EGFR is a known oncogenic driver, its specific ligand-receptor interactions in the tumor microenvironment for HER2+ and TNBC might differ from those observed in normal tissue, or may involve other cell types not captured by the current observation (e.g., aneuploid epithelial cells if such interactions were not significant). This emphasizes the need for cell-type-specific and condition-specific targeting strategies.

15. Condition-Specific Cell-Cell Interaction Patterns in Breast Cancer Subtypes

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates statistically significant differences in cell-cell interactions (CCI) across various breast cancer conditions (ER+, HER2+, Normal, TNBC) and individual samples. The dot plot visualizes the standardized mean interaction strength (color intensity) and the statistical significance (-log10(p) value, dot size) for selected major cell types: Epithelial cells, Fibroblasts, Macrophages, T cell CD4+, T cell CD8+, and B cells. Interactions are reported with specific ligand-receptor pairs and the inferred ploidy status (Diploid or Aneuploid) of the interacting cells, providing insights into the microenvironmental dynamics distinguishing different disease states.

Visual Summary

The dot plot reveals distinct and condition-specific patterns of cell-cell interactions.

Biological Interpretation

The observed condition-specific CCI patterns provide critical biological insights into breast cancer pathogenesis.

  1. Extracellular Matrix (ECM) Remodeling and Adhesion:
  1. Immune Evasion and Activation:
  1. Growth Factor Signaling and Proliferation:
  1. Role of Aneuploid Cells: The distinct interaction profiles of aneuploid cells, particularly in TNBC, are crucial. Aneuploid epithelial cells are likely the malignant tumor cells. Their interactions with aneuploid fibroblasts and macrophages suggest a co-evolution and close collaboration within the TME, where aneuploid stromal cells might be reprogrammed to support tumor growth and immune suppression. The presence of interactions like SPP1-integrin (in Epi(AneuP)|Mac(AneuP) within TNBC) further supports an aggressive, pro-metastatic phenotype, as SPP1 (Osteopontin) is a known factor promoting tumor progression and macrophage infiltration [6].

Clinical or Translational Implications

The identification of condition-specific and ploidy-dependent cell-cell interactions offers several potential clinical and translational implications:

---

References:

[1] Hynes, R. O. (2002). Integrins: Bidirectional allosteric signaling machines. Cell, 110(6), 673-687. PubMed Search: Integrins in cancer

[2] Nectin-2 (PVRL2) on GeneCards: https://www.genecards.org/cgi-bin/carddisp.pl?gene=PVRL2

[3] TIGIT on GeneCards: https://www.genecards.org/cgi-bin/carddisp.pl?gene=TIGIT

[4] CXCL12 on GeneCards: https://www.genecards.org/cgi-bin/carddisp.pl?gene=CXCL12

[5] HBEGF on GeneCards: https://www.genecards.org/cgi-bin/carddisp.pl?gene=HBEGF

[6] SPP1 on GeneCards: https://www.genecards.org/cgi-bin/carddisp.pl?gene=SPP1

16. Epithelial Cell Condition-Specific Surfaceome Markers in Breast Cancer Subtypes

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes condition-specific surfaceome markers within Epithelial cells, which are considered the tumor-origin cells, across different breast cancer subtypes (ER+, HER2+, TNBC) and Normal breast tissue. The dot plot displays the expression levels (color intensity) and the fraction of cells expressing each gene (dot size) for up to 50 surfaceome markers per condition, facilitating the identification of unique molecular signatures. Samples are further stratified by inferred ploidy status (Diploid vs. non-Diploid/Aneuploid) where indicated by the prefix "Diploid".

Visual Summary

The dot plot effectively illustrates distinct patterns of surfaceome marker expression across the four conditions (ER+, HER2+, Normal, TNBC).

Biological Interpretation

The analysis successfully identifies unique surfaceome signatures for Epithelial cells in different breast cancer subtypes, reflecting their distinct molecular pathologies.

Clinical or Translational Implications

The identified condition-specific surfaceome markers have significant potential for clinical applications, particularly in diagnostics, prognostics, and therapeutic targeting.

References

  1. MUC1: GeneCards entry for MUC1. https://www.genecards.org/cgi-bin/carddisp.pl?gene=MUC1
  2. CA12: GeneCards entry for CA12. https://www.genecards.org/cgi-bin/carddisp.pl?gene=CA12
  3. ERBB2: GeneCards entry for ERBB2. https://www.genecards.org/cgi-bin/carddisp.pl?gene=ERBB2
  4. MET: GeneCards entry for MET. https://www.genecards.org/cgi-bin/carddisp.pl?gene=MET
  5. SLC2A1: GeneCards entry for SLC2A1. https://www.genecards.org/cgi-bin/carddisp.pl?gene=SLC2A1
  6. GPNMB: GeneCards entry for GPNMB. https://www.genecards.org/cgi-bin/carddisp.pl?gene=GPNMB
  7. ERBB3 in breast cancer resistance: PubMed search for "ERBB3 breast cancer resistance". https://pubmed.ncbi.nlm.nih.gov/?term=ERBB3+breast+cancer+resistance
  8. GLUT1 inhibitors in cancer: PubMed search for "GLUT1 inhibitors cancer". https://pubmed.ncbi.nlm.nih.gov/?term=GLUT1+inhibitors+cancer
  9. CD47 in cancer immunotherapy: GeneCards entry for CD47. https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD47

17. Macrophage Condition-Specific Surfaceome Markers in Breast Cancer

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes condition-specific surfaceome markers for Macrophage cells across different breast cancer conditions (Normal and TNBC) using single-cell RNA sequencing data. The dot plot displays the mean expression level (color intensity) and the fraction of cells expressing each marker (dot size) for each sample. The markers were selected to be surfaceome-only and relatively specific to different conditions, providing insights into the distinct phenotypes of macrophages in normal breast tissue versus Triple-Negative Breast Cancer (TNBC).

Visual Summary

The dot plot effectively visualizes macrophage surfaceome marker expression across individual samples, grouped by condition (Normal and TNBC).

Biological Interpretation

The distinct surfaceome marker profiles highlight a significant phenotypic shift in macrophages in the TNBC microenvironment compared to normal breast tissue, indicative of differential functional polarization.

Clinical or Translational Implications

The identified condition-specific surfaceome markers in macrophages offer significant clinical and translational potential, particularly for TNBC.

18. Fibroblast Condition-Specific Surfaceome Markers in Breast Cancer

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis aimed to identify surfaceome markers specifically expressed by Fibroblasts across different breast cancer subtypes (ER+, HER2+, TNBC) and normal breast tissue samples. By focusing on surfaceome markers, the goal is to pinpoint genes that are expressed on the cell surface, making them potentially accessible for targeted therapies or serve as valuable diagnostic/prognostic biomarkers. The dot plot visualizes the mean expression level (color intensity) and the fraction of cells expressing each gene (dot size) for each sample and condition. Only surfaceome markers, up to 50 per condition, with a fold change cutoff of 1.5 and p-value of 0.05, were selected. Markers common in three or more conditions were excluded to emphasize condition-specificity.

Visual Summary

The dot plot clearly reveals distinct patterns of fibroblast surfaceome markers across the different conditions and individual samples:

The bar chart on the right indicates the number of cells per sample, showing variability in cell counts across samples, but consistent marker expression patterns within the condition-specific groups.

Biological Interpretation

The observed condition-specific surfaceome marker profiles in Fibroblasts highlight their heterogeneous roles in the breast tumor microenvironment (TME) across different cancer subtypes.

Clinical or Translational Implications

The identification of condition-specific fibroblast surfaceome markers has significant clinical and translational implications, particularly for TNBC.

19. T cell CD4+ Condition-Specific Surfaceome Marker Analysis in Breast Cancer Subtypes

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis aimed to identify surfaceome markers that are specifically enriched or differentially expressed in CD4+ T cells across different breast cancer conditions (ER+, HER2+, and TNBC) using single-cell RNA sequencing data. By focusing on surface markers, the goal is to pinpoint potential cell-surface proteins that could serve as biomarkers or therapeutic targets in a condition-specific manner for CD4+ T cells, which play critical roles in shaping the tumor immune microenvironment. The plot_markers_and_expression_dot tool was used to visualize the expression and prevalence of the top 50 condition-specific surfaceome markers for T cell CD4+ cells.

Visual Summary

The dot plot displays the expression patterns of various surfaceome markers in CD4+ T cells across individual patient samples, grouped by inferred breast cancer subtype (ER+, HER2+, and TNBC). Each row represents a distinct patient sample, and each column represents a specific surface gene. The size of each dot indicates the fraction of cells within that sample group expressing the gene, while the color intensity reflects the mean expression level of the gene in those cells. The samples were grouped by their subtype, with a clear bracket indicating the TNBC samples at the bottom.

A striking pattern emerged, showing a pronounced and widespread upregulation of numerous surfaceome markers in CD4+ T cells from TNBC (Triple-Negative Breast Cancer) samples. These markers exhibit high mean expression (dark red dots) and high prevalence (large dots) across most TNBC samples. In contrast, CD4+ T cells from ER+ (Estrogen Receptor-positive) and HER2+ (HER2-positive) breast cancer samples generally showed sparser and less intense expression of these specific markers. While some ER+ samples (e.g., ER-MH0029-7C, ER-AH0319) did display expression of a few markers, the overall signature was much less prominent compared to TNBC. The bar plots on the right indicate the number of CD4+ T cells contributing to each sample's measurement, which provides context for the robustness of the marker detection.

Biological Interpretation

The differential expression of surfaceome markers in CD4+ T cells across breast cancer subtypes suggests distinct functional states and roles for these cells within the tumor microenvironment.

  1. Enriched Immune Activity in TNBC CD4+ T cells: The extensive array of upregulated surfaceome markers in TNBC CD4+ T cells points towards a highly activated, perhaps dysregulated, or immunosuppressive phenotype. TNBC is known to be a more immunogenic subtype of breast cancer, often characterized by higher tumor-infiltrating lymphocytes (TILs) compared to ER+ or HER2+ subtypes. The observed marker signature aligns with this understanding.
  2. Key Surface Markers and Their Potential Functions in TNBC:
  1. Comparatively Milder Phenotype in ER+ and HER2+ CD4+ T cells: The absence of a strong, consistent surfaceome signature in ER+ and HER2+ CD4+ T cells, relative to TNBC, might indicate a less inflamed or immunogenically active tumor microenvironment, or that their condition-specific features are driven by different sets of markers not captured in this selection.

Clinical or Translational Implications

The identified condition-specific surfaceome markers in CD4+ T cells, particularly in TNBC, offer several exciting clinical and translational avenues:

Therapeutic Target Identification in TNBC:

20. Differential Expression of Cell Cycle Genes in Epithelial Cells Across Breast Cancer Subtypes

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the expression levels of a curated set of cell cycle-related genes within the Epithelial cell population across various breast cancer conditions (ER+, HER2+, TNBC) and compared to Normal breast tissue. The aim is to identify statistically significant differences in gene expression that may contribute to distinct biological characteristics of these breast cancer subtypes. Boxplots illustrate the distribution of gene expression (sample mean) for each gene across the four conditions, with statistical significance indicated for pairwise comparisons.

Visual Summary

The visualization presents boxplots for 24 selected cell cycle-related genes in Epithelial cells, comparing their expression across ER+, HER2+, Normal, and TNBC conditions.

  1. General Trends in Cancer Subtypes: Many cell cycle progression genes (e.g., *ANAPC11*, *CDC16*, *CDC26*, *CDK6*, *CUL1*, *E2F3*, *E2F4*, *HDAC1*, *HDAC2*, *MCM3*, *ORC4*, *PCNA*, *TFDP2*) show a general trend of increased expression in breast cancer subtypes, particularly in Triple-Negative Breast Cancer (TNBC), compared to Normal epithelial cells. This suggests an enhanced proliferative state in these cancer cells.
  2. Downregulation of Growth Inhibitors: Conversely, several genes known to inhibit cell cycle progression or mediate DNA damage response, such as *CDKN1A* (p21), *GADD45A*, *GADD45B*, *GADD45G*, *SFN* (14-3-3 sigma), *SMAD2*, *SMAD3*, and *SMAD4*, exhibit significantly lower expression in one or more cancer subtypes (ER+, HER2+, TNBC) compared to Normal tissue. This indicates a potential loss of crucial regulatory checkpoints and growth suppression mechanisms in cancer.
  3. TNBC as a Highly Proliferative Subtype: TNBC consistently displays the highest expression levels for many cell cycle drivers (e.g., *ANAPC11*, *CDC16*, *CDC26*, *CDK6*, *CUL1*, *E2F3*, *HDAC1*, *HDAC2*, *PCNA*, *TFDP2*), often with statistically significant increases compared to Normal tissue and other subtypes (ER+, HER2+). This aligns with the aggressive and highly proliferative nature of TNBC.
  4. Mixed Patterns in ER+ and HER2+: ER+ and HER2+ subtypes show more varied expression patterns. While some proliferation markers are elevated (e.g., *MCM3* and *ORC4* in HER2+), many genes associated with cell cycle promotion are not significantly different from Normal or are even downregulated (e.g., *CCND3*, *CCNH*).
  5. Unexpected Observations:
  1. 14-3-3 Protein Family (YWHA genes): Members of the YWHA family show diverse expression patterns. For instance, *YWHAE* is significantly higher in HER2+, while *YWHAH* is notably lower in ER+ and HER2+ compared to Normal, highlighting their complex and context-dependent roles in cell cycle regulation.

Biological Interpretation

The observed differential expression of cell cycle genes in epithelial cells provides critical insights into the molecular mechanisms driving breast cancer progression and subtype-specific characteristics:

Clinical or Translational Implications

The differential expression patterns of cell cycle genes have significant clinical and translational implications:

References

  1. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. *Cell*, 144(5), 646-674. PubMed Search: "Hallmarks of cancer"
  2. Bradner, J. E., Licklider, L. J., & Allis, C. D. (2010). Histone deacetylase inhibitors for cancer therapy. *Nature Reviews Drug Discovery*, 9(1), 23-37. PubMed Search: "HDAC inhibitors cancer therapy"
  3. Abbas, T., & Dutta, A. (2009). p21 in cancer: cellular mechanisms and therapeutic opportunities. *Cancer Research*, 69(15), 6328-6332. GeneCards: CDKN1A
  4. Hermeking, H. (2000). The 14-3-3 protein SFN (stratifin). *Nature Reviews Molecular Cell Biology*, 1(3), 223-229. GeneCards: SFN
  5. Massagué, J. (2012). TGFβ signalling in context. *Nature Reviews Molecular Cell Biology*, 13(10), 616-630. PubMed Search: "TGF-beta signaling cancer"
  6. Collado, M., & Serrano, M. (2010). Senescence in tumours: it's time to talk about it. *Nature Reviews Cancer*, 10(7), 51-57. PubMed Search: "CDKN2A cancer senescence"
  7. Remeseiro, S., & Capra, J. A. (2018). Cohesin, CTCF, and the three-dimensional architecture of the genome. *FEBS Letters*, 592(24), 3848-3862. PubMed Search: "Cohesin cancer chromosome instability"

21. Epithelial Cell Gene Ontology Analysis Across Breast Tissue Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Ontology (GO) enrichment results for epithelial cells, comparing distinct conditions (Diploid, ER+, HER2+, TNBC, and Normal) against all other cells in the dataset. The Gene Set Analysis (GSA) was performed using the GO database to identify biological processes and pathways that are significantly upregulated in epithelial cells within each specific condition. The results are visualized as bar plots, with bar length representing statistical significance (negative log-transformed p-value and adjusted p-value). This approach highlights the characteristic biological activities of epithelial cells under different physiological and pathological states in the breast tissue.

Visual Summary

The bar plots display the top enriched Gene Ontology terms for epithelial cells under five different comparisons:

  1. GSA_up for Epithelial cell: Diploid_vs_others: Shows pathways enriched in diploid epithelial cells compared to all other cells in the dataset.
  2. GSA_up for Epithelial cell: ER+_vs_others: Highlights pathways enriched in ER+ epithelial cells compared to all other cells.
  3. GSA_up for Epithelial cell: HER2+_vs_others: Illustrates pathways enriched in HER2+ epithelial cells compared to all other cells.
  4. GSA_up for Epithelial cell: Normal_vs_others: Presents pathways enriched in normal epithelial cells compared to all other cells.
  5. GSA_up for Epithelial cell: TNBC_vs_others: Displays pathways enriched in TNBC epithelial cells compared to all other cells.

Across all conditions, numerous GO terms show very high statistical significance, with -log(p-val) values often exceeding 20 and -log(q-val) values often exceeding 10, indicating robust enrichment. While some general cellular processes like "Ribosome" and "Protein processing in endoplasmic reticulum" are common across most active epithelial cell states, distinct patterns emerge for normal, diploid, and different breast cancer subtypes. Cancer-associated conditions (ER+, HER2+, TNBC) show a strong enrichment for metabolic reprogramming, protein synthesis/processing, and cell cycle-related pathways. Normal and diploid epithelial cells, in contrast, highlight pathways related to basic cellular homeostasis, specific hormonal responses, and intrinsic immune/stress responses.

Biological Interpretation

Characterization of Diploid Epithelial Cells

Epithelial cells identified as Diploid show significant enrichment in the Estrogen signaling pathway and Apoptosis when compared to all other cells. This suggests that diploid epithelial cells, likely representing normal or less transformed cells, maintain strong responsiveness to estrogen and an intact programmed cell death machinery. This is crucial for mammary gland development and homeostasis, where estrogen drives proliferation balanced by apoptosis to maintain tissue architecture. Their prominent estrogen sensitivity is a fundamental characteristic of normal breast epithelium. PubMed Search: mammary epithelial cell estrogen signaling apoptosis

Biological Shifts in ER+ Breast Cancer Epithelial Cells

Epithelial cells from ER+ breast tumors exhibit a dramatic upregulation of pathways associated with:

Distinct Features of HER2+ Breast Cancer Epithelial Cells

HER2+ epithelial cells share many features with ER+ cells, particularly high activity in:

Homeostatic Pathways in Normal Epithelial Cells

Normal epithelial cells compared to others show strong enrichment in fundamental cellular processes crucial for maintaining homeostasis and tissue integrity:

Aggressive Phenotype of TNBC Epithelial Cells

Epithelial cells from Triple-Negative Breast Cancer (TNBC) display a highly aggressive transcriptional profile, characterized by intense activity in:

Clinical or Translational Implications

The distinct pathway enrichments observed across breast cancer subtypes (ER+, HER2+, TNBC) provide valuable insights for precision oncology:

22. Gene Set Enrichment Analysis (GSEA) of Breast Cancer Cell Types by Subtype

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis utilizes Gene Set Enrichment Analysis (GSEA) to identify enriched biological pathways and functions across various cell types (Epithelial cell, Fibroblast, Macrophage, T cell CD4+, T cell CD8+, B cell) within different breast cancer conditions (ER+, HER2+, TNBC) compared to "others" (all other conditions excluding the target one, which implicitly includes Normal samples). The visualization is a dot plot, where dot color represents the Normalized Enrichment Score (NES) indicating the direction and strength of enrichment (red for positive/upregulation, blue for negative/downregulation), and dot size indicates the statistical significance (-log(p-value)).

Visual Summary

The dot plot reveals distinct and shared pathway enrichment patterns across the analyzed cell types and breast cancer subtypes.

Biological Interpretation

The GSEA results provide critical insights into the underlying biological processes distinguishing breast cancer subtypes and their associated tumor microenvironment (TME).

  1. Epithelial Cell Transformation and Proliferation:
  1. Cancer-Associated Fibroblasts (CAFs) Remodeling the TME:
  1. Immune Cell Dysregulation and TME Immunosuppression:

Clinical or Translational Implications

The distinct pathway enrichments across cell types and breast cancer subtypes offer potential avenues for therapeutic intervention and biomarker discovery:

23. Discussion

The single-cell analysis of breast tissue provides profound insights into the distinct molecular and cellular mechanisms governing normal homeostasis and breast cancer progression across its major subtypes. A central finding is the robust identification of malignant epithelial cells through their pervasive aneuploidy, a hallmark of cancer that clearly distinguishes them from diploid normal and stromal cells. Copy number variation (CNV) patterns further reveal subtype-specific genomic alterations, such as the prominent ERBB2 amplification in HER2+ tumors, underscoring the genetic drivers of these cancers. Importantly, many 'unassigned' cells in tumor samples exhibit CNV patterns identical to malignant epithelial cells, suggesting they are also tumor cells that have undergone transcriptional shifts, emphasizing the need for multi-modal annotation in cancer.

The tumor microenvironment (TME) undergoes dramatic remodeling in breast cancer. Normal breast tissue is characterized by stable epithelial-fibroblast interactions crucial for structural integrity and homeostasis, rich in extracellular matrix (ECM) and growth factor signaling. In contrast, all breast cancer subtypes show profound alterations in the TME, characterized by a shift from ILC/NK cell dominance in normal tissue to a T cell-centric immune landscape. TNBC consistently emerges as the most immunogenically active, with the highest proportions of cytotoxic T cells. However, this is often accompanied by significant immune suppression, as evidenced by elevated regulatory T cells (Tregs) in ER+ tumors and a shift towards pro-tumorigenic M2-like macrophage subsets (M2A, M2C, M2D) in TNBC, despite an overall increase in M1 macrophages across all cancer types. The reduced presence of Lymphoid Tissue Inducer (LTI) cells in all cancer subtypes further suggests impaired immune compartmentalization within the TME.

Cell-cell interaction analysis reveals subtype-specific communication networks. While normal tissue relies on broad ECM and growth factor-mediated interactions, cancer TMEs are characterized by specific, often immunosuppressive, or pro-tumorigenic interactions. The TGFB1-TGFbeta_receptor1 interaction among macrophages is remarkably conserved and prominent in both HER2+ and TNBC, suggesting a critical and persistent immunosuppressive axis. TNBC, in particular, demonstrates a highly activated TME, with widespread interactions involving aneuploid epithelial cells, activated fibroblasts (CAFs), and macrophages. Key interactions include immune checkpoints (NECTIN2-TIGIT, CD86-CTLA4), growth factor pathways (HBEGF-ERBB2), and stemness-associated Notch signaling (JAG1-NOTCH2) in aneuploid epithelial cells. Cancer-associated fibroblasts in TNBC display a unique surfaceome signature, marked by FAP, PDGFRB, and MMP14, reflecting their active role in ECM remodeling and immune modulation.

Intrinsic to the epithelial cells, subtype-specific surfaceome markers (e.g., ESR1 in ER+, ERBB2 in HER2+, SLC2A1, GPNMB, CD47 in TNBC) and distinct Gene Ontology enrichments are observed. All cancer epithelial cells show increased proliferative activity, evidenced by upregulated cell cycle drivers and downregulated inhibitors, especially pronounced in TNBC. Metabolic reprogramming (oxidative phosphorylation, glycolysis) is also a consistent feature across cancer epithelial cells and fibroblasts. These findings highlight the complex interplay between genomic instability, aberrant cell-intrinsic signaling, and dynamic TME interactions that collectively drive breast cancer progression, offering a rich resource for identifying novel therapeutic targets and biomarkers.

Hypotheses:

  1. The 'unassigned' aneuploid cells in breast cancer samples represent malignant epithelial cells that have undergone transcriptional reprogramming, leading to a loss of canonical epithelial markers but retaining genomic instability.
  2. The balance between cytotoxic T cells and regulatory T cells, in conjunction with the specific polarization states of macrophages (M1 vs. M2 subtypes), is a critical determinant of immune checkpoint inhibitor responsiveness across breast cancer subtypes, particularly in TNBC where both effector T cells and immunosuppressive macrophages are abundant.
  3. Activated cancer-associated fibroblasts (CAFs), characterized by markers such as FAP and PDGFRB, actively remodel the extracellular matrix and engage in specific cell-cell interactions (e.g., via SPP1-integrin) that promote tumor cell invasion, metastasis, and immune evasion in TNBC.
  4. The conserved and prominent TGFB1-TGFbeta_receptor1 signaling between macrophages in HER2+ and TNBC establishes a central and targetable immunosuppressive axis that limits anti-tumor immunity.
  5. The paradoxical upregulation of CDKN2A/B in highly proliferative TNBC epithelial cells represents a non-functional stress response or a mechanism for inducing senescence in a subset of tumor cells, rather than an effective tumor-suppressive mechanism.

Potential therapeutic targets:

  1. TGFB1-TGFbeta_receptor1 pathway: This pathway is consistently active in macrophages within HER2+ and TNBC tumors, promoting an immunosuppressive and pro-tumorigenic microenvironment. Targeting it could reprogram macrophages to an anti-tumor phenotype. Evidence: Strong and persistent TGFB1-TGFbeta_receptor1 interaction between macrophages in both HER2+ and TNBC, even when other interactions are lost (Section 14). TGF-beta is a known immunosuppressive cytokine (Section 12). Validation: Preclinical studies using TGF-beta inhibitors in breast cancer models to assess macrophage reprogramming, enhanced anti-tumor immunity, and reduced tumor growth or metastasis.
  2. FAP (Fibroblast Activation Protein alpha): FAP is a highly specific and prevalent marker for activated cancer-associated fibroblasts (CAFs) in TNBC, which play critical roles in ECM remodeling, immune suppression, and tumor progression. Targeting FAP could deplete or reprogram these pro-tumorigenic fibroblasts. Evidence: High and specific expression of FAP in TNBC-associated Fibroblasts (Section 18). Validation: Clinical trials or preclinical studies utilizing FAP-targeting antibody-drug conjugates (ADCs) or FAP-CAR-T cells in TNBC patients or models.
  3. ERBB2 (HER2): ERBB2 is the defining oncogene and primary driver for HER2+ breast cancer. Its overexpression is critical for tumor cell proliferation and survival. Evidence: Very high expression and prevalence of ERBB2 in HER2+ epithelial cells (Section 16). ErbB signaling pathway is highly enriched in HER2+ epithelial cells (Section 21). Validation: Continued clinical development and optimization of anti-HER2 targeted therapies (e.g., trastuzumab, pertuzumab, T-DM1, tucatinib) and novel inhibitors to overcome resistance.
  4. CTLA4 (Cytotoxic T-lymphocyte-associated protein 4): CTLA4 is a critical inhibitory immune checkpoint receptor highly expressed on CD4+ T cells in TNBC, contributing to immune evasion and T cell exhaustion. Blocking CTLA4 can enhance anti-tumor T cell responses. Evidence: Prominent expression of CTLA4 on CD4+ T cells in TNBC samples (Section 19). Validation: Investigate anti-CTLA4 immunotherapies (e.g., ipilimumab) as monotherapy or in combination with other agents to unleash anti-tumor immunity in TNBC patients.
  5. JAG1-NOTCH2 pathway: Notch signaling, specifically the JAG1-NOTCH2 interaction, is highly active in aneuploid epithelial cells of TNBC and is implicated in cell fate decisions, cancer stemness, and tumor progression, suggesting it's a key driver of aggressive TNBC features. Evidence: JAG1-NOTCH2 interaction strongly observed in aneuploid epithelial cells in TNBC (Section 12). Validation: Preclinical evaluation of Notch pathway inhibitors in TNBC models, assessing effects on tumor growth, stemness, and recurrence.

Follow-up validation ideas:

  1. Perform Fluorescence In Situ Hybridization (FISH) or comparative genomic hybridization (CGH) on sorted 'unassigned' aneuploid cells and malignant epithelial cells to independently validate shared CNV patterns and confirm their malignant identity.
  2. Quantify T cell and macrophage subset proportions (e.g., CD8+ T cells, Tregs, M1/M2 macrophages via CD163/LYVE1/FCGR1A/ITGB8) in larger patient cohorts using flow cytometry or multiplex immunohistochemistry (IHC) to validate population shifts and correlate with clinical outcomes or treatment response.
  3. Utilize spatial transcriptomics or multiplexed imaging (e.g., CyTOF, CODEX) to map the precise localization and interaction patterns of key immune and stromal cell types (e.g., FAP+ fibroblasts, M2-like macrophages, CTLA4+ T cells) within the breast cancer TME and confirm cell-cell interaction findings.
  4. Employ in vitro co-culture systems with primary breast cancer epithelial cells, CAFs, and TME immune cells to functionally test specific ligand-receptor interactions (e.g., blocking JAG1-NOTCH2, HBEGF-ERBB2, NECTIN2-TIGIT) and assess their impact on proliferation, invasion, and immune cell function.
  5. Validate the protein expression of identified subtype-specific surfaceome markers (e.g., FAP, PDGFRB on CAFs; FCGR1A, ITGB8 on macrophages; SLC2A1, GPNMB on epithelial cells) using mass spectrometry-based proteomics or flow cytometry on patient-derived cell populations and correlate with disease stage and subtype.
  6. Conduct targeted perturbation experiments using CRISPR/Cas9 or RNAi in breast cancer organoid models to inhibit key cell cycle regulators (e.g., CDK6, CDKN1A) or metabolic pathways (e.g., SLC2A1) identified as differentially expressed in epithelial cells and evaluate their impact on tumor growth and survival.

Limitations:

This report is based on single-cell RNA sequencing data, which provides correlative insights into cellular states and interactions rather than direct causality; functional validation is required. The CNV estimates are inferred from gene expression, not direct genomic sequencing, and represent population-level averages within clusters. Cell-cell interaction analyses rely on known ligand-receptor pairs, potentially missing novel or uncharacterized interactions. The static nature of single-cell sequencing captures a snapshot, not dynamic cellular processes or temporal evolution of the TME. While robust, some minor cell subsets (e.g., macrophage M1/M2 polarization) required further specific marker analysis for finer distinction. Finally, the findings are derived from a specific cohort and require validation in larger, independent patient cohorts to ensure generalizability.

24. Query List

  1. Show UMAP with Condition, Sample, major cell type, minor cell type, ploidy_dec, and celltype_subset in 2 columns and save it.
  2. Show major cell type scores on UMAP and save it.
  3. Show the overall Celltype_subset marker expression dot plot and save it. Keep target_cell as None and keep the other arguments at their default values.
  4. Select tumor-origin cells and unassigned cells, group them by sample, show CNV heatmap, and also show a summary of significantly amplified copy number regions, then save it.
  5. Show CNV patterns on UMAP. Include major cell type, minor cell type, ploidy results, condition, and sample in 2 columns and save it.
  6. Show population bar plot for minor cell types and save it.
  7. Show subset population barplot for T cell and save it.
  8. For T cell subset population, find and show boxplots for significant differences between conditions and save it. Set ncols appropriately considering the total number of panels.
  9. Show subset population barplot for macrophage and save it.
  10. For macrophage subset population, find and show boxplots for significant differences between conditions and save it. Set ncols appropriately considering the total number of panels.
  11. Select tumor-origin cells and unassigned cells, show ploidy population as a barplot for them, and save it.
  12. Show cell-cell interaction patterns among Epithelial cell, Fibroblast, Macrophage, and T cell by condition and save it. For cell-cell interactions, select up to 80 per condition.
  13. Show cell-cell interactions by condition and save the result. Select at most 80 cell-cell interactions for each condition.
  14. Select only genes related to immune checkpoint and cell cycle pathways, show cell-cell interactions for these genes, and save it.
  15. Find and show dot plot for statistically significant differences in cell-cell interactions among Epithelial cell, Fibroblast, Macrophage, T cell CD4+, T cell CD8+, B cell by condition and save it. Set max_n_items_per_group = 25.
  16. Show the condition-specific markers for tumor-origin cells (Epithelial cell) as a dot plot and save the result. Use only surfaceome markers, up to 50 markers per condition.
  17. Extract condition-specific markers for Macrophage, show as dotplot, and save it. Only surfaceome markers, up to 50 per condition.
  18. Extract condition-specific markers for Fibroblast, show as dotplot, and save it. Only surfaceome markers, up to 50 per condition.
  19. Extract condition-specific markers for T cell CD4+, show as dotplot, and save it. Only surfaceome markers, up to 50 per condition.
  20. For Epithelial cell, select genes related to cell cycle pathways that show statistically significant expression differences by condition, show boxplots, and save it. Set max_n_items_to_plot = 24, and set ncols appropriately to achieve an aspect ratio of approximately 2x3.
  21. Show Gene Ontology (GSA) analysis results for epithelial cells as bar plots and save the result.
  22. Show dotplot of Gene Set Enrichment Analysis results for Epithelial cell, Fibroblast, Macrophage, T cell CD4+, T cell CD8+, B cell, and save it. Set color map to RdBu_r and n_pws_to_show = 80.
Top